SAFETY
Data

Trulance established safety and
tolerability across 2 indications1

Treatment-related diarrhea was observed in ≤5% of patients1

No additional adverse events (AEs) occurred at an incidence of ≥2% in patients and at an incidence greater than placebo1

Most common
AEs in CIC1CIC

AE

Trulance 3 mg
(n=863)
%
Placebo
(n=870)
%

Diarrhea

5.0%
1.0%

Severe diarrhea was reported in 0.6% of patients receiving Trulance vs 0.3% of placebo-treated patients1

4% discontinuation rate for Trulance vs 2% for placebo1

2% discontinuation rate due to diarrhea vs 0.5% for placebo1

Reported in at least 2% of Trulance-treated patients with CIC and at an incidence greater than placebo1

Most common
AEs in IBS-C1IBS-C

AE

Trulance 3 mg
(n=723)
%
Placebo
(n=726)
%

Diarrhea

4.3%
1.0%

Severe diarrhea was reported in 1% of patients receiving Trulance vs 0.1% of placebo-treated patients1

2.5% discontinuation rate for Trulance vs 0.4% for placebo1

1.2% discontinuation rate due to diarrhea vs 0% for placebo1

Reported in at least 2% of Trulance-treated patients with IBS-C and at an incidence greater than placebo1

Minimally absorbed with
negligible systemic availability1

No drug-drug
interactions observed1

If severe diarrhea occurs, suspend dosing
and rehydrate the patient1

Indication

Trulance (plecanatide) 3 mg tablets is indicated in adults for the treatment of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
Trulance® is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile mice administration of a single oral dose of plecanatide caused deaths due to dehydration. Use of Trulance should be avoided in patients 6 years to less than 18 years of age. The safety and efficacy of Trulance have not been established in pediatric patients less than 18 years of age.

 

Contraindications
  • Trulance is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • Trulance is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
Risk of Serious Dehydration in Pediatric Patients
  • Trulance is contraindicated in patients less than 6 years of age. The safety and effectiveness of Trulance in patients less than 18 years of age have not been established. In young juvenile mice (human age equivalent of approximately 1 month to less than 2 years), plecanatide increased fluid secretion as a consequence of stimulation of guanylate cyclase-C (GC-C), resulting in mortality in some mice within the first 24 hours, apparently due to dehydration. Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than older patients to develop severe diarrhea and its potentially serious consequences.
  • Use of Trulance should be avoided in patients 6 years to less than 18 years of age. Although there were no deaths in older juvenile mice, given the deaths in young mice and the lack of clinical safety and efficacy data in pediatric patients, use of Trulance should be avoided in patients 6 years to less than 18 years of age.
Diarrhea
  • Diarrhea was the most common adverse reaction in the four placebo-controlled clinical trials for CIC and IBS-C. Severe diarrhea was reported in 0.6% of Trulance-treated CIC patients, and in 1% of Trulance-treated IBS-C patients.
  • If severe diarrhea occurs, the health care provider should suspend dosing and rehydrate the patient.
Adverse Reactions
  • In the two combined CIC clinical trials, the most common adverse reaction in Trulance-treated patients (incidence ≥2% and greater than in the placebo group) was diarrhea (5% vs 1% placebo).
  • In the two combined IBS-C clinical trials, the most common adverse reaction in Trulance-treated patients (incidence ≥2% and greater than in the placebo group) was diarrhea (4.3% vs 1% placebo).

Please also see the full Prescribing Information, including BOXED Warning, for additional risk information.